Radiotherapy in painting dose on histoscannographic mappingStandard pan-sinusal Radiotherapy
Radiotherapy in painting dose on histoscannographic mapping: The target volumes to be delineated are as follows:
* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).
* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone).
Standard pan-sinusal Radiotherapy: The target volumes to be delineated are as follows:
* High-risk CTV, including the entire post-operative cavity,
* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone).
Study summary
The patient is randomized to one of the following groups:
* Experimental group: Radiotherapy in painting dose on histoscannographic mapping
* Control group: standard pan-sinus radiotherapy
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients \>18 years of age
* Patient with a histologically confirmed malignant tumor of the sinuses, any histological type except melanoma, lymphoma, mesenchymal tumors (sarcoma)
* Patient treated by endoscopic sinonasal surgery with histosurgical mapping within 2 months prior to radiotherapy
* Indication for radiotherapy treatment (photontherapy or protontherapy), without neoadjuvant chemotherapy (concomitant chemotherapy is permitted)
* Signature of informed consent prior to any specific study procedure
* Subject affiliated to a social security system
Exclusion Criteria:
* Patient with not operated in place tumor
* Patient with distant metastases
* Patient treated with neoadjuvant chemotherapy
* Pregnant or breast-feeding woman or absence of contraception during genital activity
* History of any other malignant disease in the last 3 years, except basal cell skin cancer, carcinoma in situ or superficial bladder tumor. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and show no sign of recurrence for at least 3 years.
* Simultaneous participation in another therapeutic clinical trial
* Patients deprived of their liberty, under guardianship, under curatorship, or subject to a legal protection measure, or unable to express their consent.
* Patients unable to undergo trial monitoring for geographical, social or psychopathological reasons
Primary outcome measure(s)
Occurrence of radiation-induced nasal, ocular, auditory, endocrine and cerebral mucosal toxicities — Toxicity grade ≥ 2 according to NCI-CTCAE V5.0 within 3 months of the end of IMRT. Proportion of patients who do not develop radiation-induced mucosal, ocular, auditory, endocrine and/or nervous system toxicity grade ≥ 2 according to NCI-CTCAE V5.0 within 3 months of the end of IMRT.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
